Mitomycin (Zusduri)
Customize your policy alerts
Sign up for blue cross blue shield - tennessee Policy ID_CHS_70372026_1126 alerts
Get alerted when Policy ID_CHS_70372026_1126 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization coverage of intravesical Zusduri (mitomycin) for adult members with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and compendial non-muscle invasive bladder cancer use. Coverage requires satisfaction of the stated treatment criteria and absence of exclusions.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.